Evidence map›Paper›PMID 26250739›Full record

ReviewNature reviews. Immunology2015

Immunopathology of multiple sclerosis.

Calliope A Dendrou, Lars Fugger, Manuel A Friese

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,136 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,136citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05245344 unknown statusnot on this mapstarted 2022, after this paper: background citation

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

TypeobservationalSponsorNeuromed IRCCSRan2022 to 2023Enrolled154ConditionsRelapsing-Remitting Multiple Sclerosis (RRMS), Neuromyelitis Optica, HealthyArmsPeripheral blood withdrawal
NCT05973929 unknown statusnot on this mapstarted 2022, after this paper: background citation

Clinical and Radiological Evaluation of Movement Disorders in Multiple Sclerosis Patients.

TypeobservationalSponsorAl-Azhar UniversityRan2022 to 2024Enrolled57ConditionsMultiple Sclerosis, Movement DisordersArmsScreen for movement disorder and correlates it with MRI findings.
3 · Its place in the literature

Who cites it

1,136 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. T Cell Thoughts.Immunological reviews · 2026
    Review
  19. Review
  20. Review

1,076 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Calliope A DendrouNuffield Department of Clinical Neurosciences, Division of Clinical Neurology and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
Lars FuggerNuffield Department of Clinical Neurosciences, Division of Clinical Neurology and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
Manuel A FrieseInstitut für Neuroimmunologie und Multiple Sklerose, Zentrum für Molekulare Neurobiologie Hamburg, Universitätsklinikum Hamburg-Eppendorf, 20246 Hamburg, Germany.

Funding

Medical Research CouncilWellcome Trust 100308
6 · The paper itself

Abstract

Two decades of clinical experience with immunomodulatory treatments for multiple sclerosis point to distinct immunological pathways that drive disease relapses and progression. In light of this, we discuss our current understanding of multiple sclerosis immunopathology, evaluate long-standing hypotheses regarding the role of the immune system in the disease and delineate key questions that are still unanswered. Recent and anticipated advances in the field of immunology, and the increasing recognition of inflammation as an important component of neurodegeneration, are shaping our conceptualization of disease pathophysiology, and we explore the potential implications for improved healthcare provision to patients in the future.

Indexed as

AutoimmunityEnvironmental ExposureGenetic Predisposition to DiseaseHumansInflammationMultiple Sclerosis

Identifiers

PMID26250739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.